In our study we tried to assess the potential of MMP-3, MMP-7, MMP-10, and MMP-26, which showed significant differences in concentrations between the groups of healthy women, dysplasia patients, and cancer patients, and also demonstrated the ability to distinguish benign from malignant lesions. This evidence concerns the gene MMP26 and dysplasia.